News
-
-
-
-
PRESS RELEASE
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Onco-Innovations completes successful 300g scale-up batch of A83B4C63, achieving 99.3% purity for API under ONC010 PNKP Inhibitor Technology. Dave Antony appointed as CFO -
-
PRESS RELEASE
Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
Onco-Innovations announces successful completion of a pilot project with Kuano Ltd., advancing its PNKP Inhibitor Technology through AI and quantum-based computational approaches -
-
PRESS RELEASE
Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology
Onco-Innovations starts process development & scale-up activities for A83B4C63, advancing towards clinical trials. Collaboration with Dalton Pharma Services to optimize production processes and ensure regulatory readiness -
-
PRESS RELEASE
Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program
Onco-Innovations partners with Nanosoft Polymers for polymer process and drug formulation optimization activities. Appointment of Dave Antony as VP Corporate Finance announced
